3 January 2019 - Bausch & Lomb today announced that on 27 December 2018, Health Canada issued the notice of compliance for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%). 

Vyzulta the first prostaglandin analog with one of its metabolites being nitric oxide, is indicated for the reduction of intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.

Vyzulta is the first new innovative treatment for open-angle glaucoma in Canada in almost twenty years.

Read Bausch Health press release